Deborah A Marshall, Brittany Gerber, Gillian R Currie, Jordi Antón, Lien De Somer, Michelle Dey, Tsipi Egert, Yona Egert, Lia Henan, Jens Klotsche, Laura Martinez Mifsut, Kirsten Minden, Christophe Normand, David Porte, Rotraud K Saurenmann, Joost F Swart, Yosef Uziel, Jennifer Wilson, Carine Wouters, Amit Ziv, Susanne M Benseler
BACKGROUND: Juvenile idiopathic arthritis (JIA) refers to a heterogeneous group of rheumatic conditions in children. Novel drugs have greatly improved disease outcomes; however, outcomes are impacted by limited awareness of the importance of early diagnosis and adequate treatment, and by differences in access across health systems. As a result, patients with JIA continue to be at risk for short- and long-term morbidity, as well as impacts on virtually all aspects of life of the child and family...
August 9, 2024: Pediatric Rheumatology Online Journal